Navigation Links
Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agent Omniscan
Date:3/5/2008

GREAT NECK, N.Y., March 5 /PRNewswire/ -- Parker Waichman Alonso LLP announces that it has filed suit on behalf of a man diagnosed with Nephrogenic Systemic Fibrosis (NSF) after receiving two injections of Omniscan, a gadolinium contrast dye manufactured by General Electric Company, its subsidiaries and Novation LLC. NSF is a debilitating, often fatal disease that robs patients of their mobility. NSF is a condition that affects patients with pre-existing kidney disease who have been exposed to gadolinium contrast dyes such as Omniscan. Symptoms of NSF include thickening and hardening of the skin, joint problems, muscle weakness and eye discoloration. The lawsuit was filed in the US District Court for the Eastern District of Pennsylvania (Docket Number: 2:08-cv-1060)

Zbigniew Marcinczyk, a resident of Philadelphia and a patient with pre-existing kidney disease, received two injections of gadolinium contrast dye in September and December 2005. Representatives from Holy Redeemer Hospital and the University of Pennsylvania Hospital in Philadelphia have confirmed that the gadolinium contrast dye administered to Marcinczyk was Omniscan. Shortly after the administration of Omniscan, Marcinczyk developed and continues to suffer from the severe, debilitating and progressive fibrotic changes associated with NSF. This has permanently disabled, disfigured and severely impaired the plaintiff.

The lawsuit alleges that the chemical make-up of Omniscan makes it more likely that gadolinium will become free within the bodies of recipients, thereby making it more likely that kidney patients will develop NSF. The lawsuit further alleges that Omniscan is defective, and that the defendants failed to adequately test Omniscan and failed to warn patients about its potential to cause NSF. In September 2007, the Food & Drug Administration (FDA) asked the manufacturers of gadolinium contrast dyes to add a black box warning to the product labels about its association with NSF. The FDA also warned that patients with kidney disease should avoid gadolinium contrast agents. NSF is a devastating condition characterized by high blood pressure, burning, itching, swelling and hardening of the skin. Other symptoms include red or dark patches on the skin; pain deep in the hip bones or ribs and muscle weakness. NSF can progress to the point of causing severe stiffness in joints, and it can lead to death. There is currently no cure for NSF.

On February 29, the U.S. Judicial Panel on Multidistrict Litigation designated the U.S. District Court for the Northern District of Ohio as the venue for the many lawsuits that have been filed, and those that will be filed in federal district court, against the makers of gadolinium contrast dyes. An estimated 68 cases have been filed in more than a dozen different federal districts against gadolinium contrast dye manufacturers, including General Electric Company. The panel indicated that the Northern District Of Ohio provides a relatively central forum for the centralization of this nationwide litigation.

If you or a loved one has developed NSF after being administered a gadolinium contrast dye, please contact our office by visiting http://www.yourlawyer.com. Free case evaluations are also available by calling 1-800-LAW-INFO (1-800-529-4636).

About Parker Waichman Alonso LLP

Parker Waichman Alonso LLP is a leading products liability and personal injury law firm that represents plaintiffs nationwide. The firm has offices in New York and New Jersey. Parker Waichman Alonso LLP has assisted thousands of clients in receiving fair compensation for injuries resulting from defective products, tainted foods, medications and medical devices.

CONTACT: Parker Waichman Alonso LLP

Fred R. Rosenthal, Managing Attorney

(800) LAW-INFO

(800) 529-4636

info@yourlawyer.com

http://www.yourlawyer.com


'/>"/>
SOURCE Parker Waichman Alonso LLP
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. National Spokeswoman Eva Longoria Parker to Accept $200,000 Donation From AT&T to Benefit PADRES Contra El Cancer
2. Parker Waichman Alonso LLP, Becnel Law Firm, LLC, Douglas & London P.C., Levin
3. Parker Waichman Alonso LLP, Along with Smith & Nevares, Salas & Co. and Becnel
4. Watson Files Application for Generic SEASONIQUE(R)
5. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
6. RealSelf.com Denies Lifestyle Lifts Trademark Claims and Files Countersuit
7. Novo Nordisk Files Annual Report with the SEC
8. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
9. Digital Healthcare Files to Enjoin Two State of Ohio Departments; Charges Bid-Steering and Breach of Agreement in Program to Control Medicaid Overpayment of Insurance Claims
10. Aircraft Medical Files Counter Action Against Verathon
11. MDS Inc. Files Restated 2007 Quarterly Reports Under US GAAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... Pixel Film ... Pro X. , "Film editors can give their videos a whole new perspective by ... Austin - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 ...
(Date:6/26/2016)... ... ... legally blind and certified personal trainer is helping to develop a weight loss fitness plan ... fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library ... City Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ... for fumigation is not a common occurrence, but a necessary one in the event that ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Belgium , June 24, 2016 ... today announced the appointment of Dr. Edward ... as a Non-Executive Director, effective June 23, 2016.Dr. ... Compensation and Nominations and Governance Committees.  As a ... will provide independent expertise and strategic counsel to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: